相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
A. Gennari et al.
ANNALS OF ONCOLOGY (2021)
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Thomas Bachelot et al.
NATURE MEDICINE (2021)
Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies
Dimitri Carene et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
R. Condorelli et al.
ANNALS OF ONCOLOGY (2019)
Cancer modeling meets human organoid technology
David Tuveson et al.
SCIENCE (2019)
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
Jianfang Liu et al.
CELL (2018)
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
Suk Hyung Lee et al.
CELL (2018)
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J. Mateo et al.
ANNALS OF ONCOLOGY (2018)
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
David M. Hyman et al.
NATURE (2018)
The European Society for Medical Oncology (ESMO) Precision Medicine Glossary
L. R. Yates et al.
ANNALS OF ONCOLOGY (2018)
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists
Marilyn M. Li et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Helen Davies et al.
NATURE MEDICINE (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Christophe Massard et al.
CANCER DISCOVERY (2017)
Implementing Genome-Driven Oncology
David M. Hyman et al.
CELL (2017)
rCGH: a comprehensive array-based genomic profile platform for precision medicine
Frederic Commo et al.
BIOINFORMATICS (2016)
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Melinda L. Telli et al.
CLINICAL CANCER RESEARCH (2016)
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau et al.
LANCET ONCOLOGY (2015)
Precision medicine for metastatic breast cancer-limitations and solutions
Monica Arnedos et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
Fabrice Andre et al.
LANCET ONCOLOGY (2014)
A community effort to assess and improve drug sensitivity prediction algorithms
James C. Costello et al.
NATURE BIOTECHNOLOGY (2014)
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis et al.
NATURE (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
The Phosphoinositide 3-Kinase Regulatory Subunit p85α Can Exert Tumor Suppressor Properties through Negative Regulation of Growth Factor Signaling
Cullen M. Taniguchi et al.
CANCER RESEARCH (2010)
分享论文
